Biologic Drugs for Crohn’s: Side Effects

Educational content only (not medical advice). If you have Crohn’s disease, you’ve probably learned two truths: (1) your immune system can be a little too enthusiastic, and (2) the internet can make any medication sound like it comes with a complimentary thunderstorm. Biologic drugs sit right in the middle of those truths. They can be life-changing for moderate to severe Crohn’sbut like any powerful therapy, they come with potential side effects worth understanding in plain, non-panicky English.

This guide breaks down common and serious side effects of Crohn’s biologics, why they happen, how risks differ by drug class, and what people typically experience day-to-dayso you can have smarter, calmer conversations with your GI team.

Biologics 101: What They Are (and Why Crohn’s Responds to Them)

Biologics are medicines made from living cells (not mixed in a garage, don’t worrymade under strict manufacturing controls). Most Crohn’s biologics are monoclonal antibodies: highly targeted proteins designed to block a specific step in the inflammation process.

Crohn’s disease involves an immune response that misfires in the digestive tract, causing chronic inflammation. Biologics don’t “turn off” the entire immune system, but they do quiet certain inflammatory signals. That targeted approach often improves symptoms and can help heal the bowel liningbut it also explains the biggest theme in side effects: infection risk goes up because parts of immune defense are dampened.

The Main Biologic Drug Classes Used for Crohn’s

Different biologics target different immune pathways. In practice, side effects can overlap, but each class has its own “greatest hits.” Here are the big categories you’ll hear about in the U.S.:

1) Anti-TNF drugs

These block tumor necrosis factor (TNF), a key inflammation driver. Examples include:

• Infliximab (IV infusion; plus biosimilars)
• Adalimumab (self-injection; plus biosimilars)
• Certolizumab pegol (self-injection)

2) Anti-integrin drugs

These reduce inflammatory cell “traffic” into the gut.

• Vedolizumab (IV or subcutaneous forms)
• Natalizumab (rarely used for Crohn’s today because of a serious brain infection risk)

3) Anti-IL-12/23 drugs

• Ustekinumab (IV loading dose, then injections)

4) Anti-IL-23 drugs

This category expanded fast recently and includes multiple options for Crohn’s.

• Risankizumab (IV induction, then injections)
• Guselkumab (Crohn’s indication approved in the U.S. in 2025)
• Mirikizumab (U.S. Crohn’s approval in 2025)

A Quick Cheat Sheet: Common vs Serious Side Effects

Most people who experience side effects get mild onesthink “annoying but manageable.” Serious events are uncommon, but because the stakes are higher, they deserve attention.

Most Common Side Effects People Report

Across biologics, the most common side effects tend to cluster into a few buckets:

• Upper respiratory infections (colds, sinus infections): more likely because immune defenses are dialed down.
• Headache and fatigue: often around dosing days, sometimes improves over time.
• Joint pain or body aches: can be tricky to separate from inflammation, stress, or Crohn’s itself.
• Nausea or stomach discomfort: sometimes medication-related, sometimes Crohn’s being Crohn’s.
• Injection-site reactions: redness, swelling, itching, warmth, or bruising where the shot went in.
• Mild rash or itching: more common with some drugs or after repeated exposure.

Important reality check: “Common” doesn’t mean “guaranteed.” Plenty of patients have minimal side effects, especially once they settle into a routine and the dosing schedule becomes less dramatic than the first few weeks.

Infusion Reactions vs Injection Reactions (What’s the Difference?)

Infusion reactions

With IV drugs (like infliximab, vedolizumab, risankizumab induction, ustekinumab loading), reactions can occur during the infusion or shortly after. They may include:

• Flushing, itching, hives, rash
• Fever/chills
• Chest tightness, shortness of breath
• Dizziness, changes in blood pressure

Infusion centers watch for this and have protocols (slowing the infusion, monitoring, medications if needed). Many people who have a mild reaction can still continue therapy safely with adjustments.

Injection reactions

With self-injected drugs (adalimumab, certolizumab, ustekinumab maintenance, IL-23 inhibitors maintenance), you may see local skin symptoms:

• Redness, swelling, itching
• Burning/stinging during injection
• A small bruise or tenderness

These often improve with technique changes (site rotation, letting medication warm slightly if allowed, proper needle angle), but always follow the medication’s instructions and your clinician’s guidance.

Serious Side Effects (Uncommon, But Worth Knowing)

Serious side effects are not the “expected” experiencebut they are the reason biologics come with screening checklists, warning labels, and follow-up appointments. Here’s what clinicians watch for most closely.

1) Serious infections (including TB and opportunistic infections)

All biologics can increase infection risk to some degree because they modify immune function. Infections can include pneumonia, severe skin infections, bloodstream infections, andparticularly with certain classesreactivation of infections that were previously quiet.

Why TB screening matters: TNF plays a role in containing tuberculosis bacteria. That’s why anti-TNF drugs have strong TB screening recommendations. Reactivation of hepatitis B is also a concern with immune-suppressing therapies, which is why labs may be checked before treatment.

2) Malignancy risk (especially highlighted for anti-TNF therapy)

Because the immune system helps with “immune surveillance” (spotting abnormal cells early), dampening immune pathways can theoretically affect cancer risk. For anti-TNF drugs, warnings include lymphoma and other malignancies, with particular attention to rare lymphoma subtypes reported in certain populations.

In real-world decision-making, your GI team weighs: Crohn’s severity, your age, prior therapies, family history, other immunosuppressants, and how uncontrolled inflammation itself can carry long-term risks.

3) Serious allergic reactions

Rarely, biologics can trigger severe hypersensitivity reactions (including anaphylaxis). Warning signs can include swelling of the face or throat, severe hives, difficulty breathing, or fainting. This is an “emergency now” situation.

4) Liver problems or elevated liver enzymes

Some biologics used in Crohn’s (including certain IL-23 inhibitors) list elevated liver blood tests as a common side effect, and more serious liver injury is rare but reported. Clinicians may monitor liver enzymes, especially if you have other risk factors.

5) Neurologic risks (rare, class-specific)

A key example is progressive multifocal leukoencephalopathy (PML), a rare brain infection linked to natalizumab. This risk is why natalizumab is generally reserved for specific situations and monitored closely, and why other gut-selective options are often preferred.

6) Heart failure and demyelinating disease (anti-TNF caution areas)

Anti-TNF drugs carry cautions in patients with certain neurologic conditions (demyelinating disease) and in people with moderate to severe heart failure. This doesn’t mean these side effects are commonit means clinicians ask the questions up front so they can choose safely.

Side Effects by Biologic Class (What Tends to Stand Out)

Anti-TNF (infliximab, adalimumab, certolizumab): what’s typical

• Common: infections (especially respiratory), headache, rash, nausea; infusion or injection reactions depending on route.
• Notable risks: serious infections (including TB), hepatitis B reactivation, certain malignancy warnings, rare neurologic and heart-related cautions.
• Practical example: Someone starts infliximab and feels fineuntil their third infusion, when they develop itching and flushing during the drip. The infusion center slows the rate, symptoms settle, and future infusions are adjusted. This is a classic “manageable reaction” pattern, not necessarily a reason therapy must stop.

Vedolizumab (anti-integrin): what’s typical

• Common: headache, joint pain, nausea, fatigue, mild infections.
• Notable theme: it’s considered more gut-selective, so systemic side effects may be less pronounced for some peoplethough serious infections can still occur and monitoring still matters.
• Practical example: A patient switches from an anti-TNF after recurrent sinus infections and finds that on vedolizumab they still get the occasional cold, but fewer “knock-you-flat” infections. That kind of difference is why switching classes can be useful.

Ustekinumab (anti-IL-12/23): what’s typical

• Common: upper respiratory infections, headache, fatigue, injection-site reactions.
• Other considerations: because it affects immune signaling, infection risk still exists; clinicians also watch for allergic reactions and rare events listed in prescribing info.

IL-23 inhibitors (risankizumab, guselkumab, mirikizumab): what’s typical

• Common: upper respiratory infections, headache, joint pain, injection-site reactions.
• Labs that may show changes: some IL-23 therapies list elevated liver tests as a common side effect in Crohn’s populations, so your GI may order periodic labs.
• Practical example: Someone on an IL-23 inhibitor feels great symptom-wise but notices their lab portal flags mildly elevated liver enzymes. Their clinician repeats labs, reviews other causes (viral illness, supplements, alcohol, other meds), and decides whether the change is temporary or needs action.

Natalizumab (rarely used): the big watch-out

The standout concern is PML. Because other effective options exist, natalizumab is usually reserved for special situations and guided by strict risk assessment and monitoring.

Why Do Side Effects Happen? (A Simple, Useful Explanation)

Most biologic side effects fall into one of three mechanisms:

1. Immune modulation: blocking inflammatory pathways can reduce defenses against infections and alter how your body responds to viruses and bacteria.
2. Immunogenicity: your body can develop antibodies to the biologic. This can make the drug less effective and can increase the chance of infusion/injection reactions in some cases.
3. Delivery method: IV infusions and injections come with their own “plumbing problems”local irritation, rate-related symptoms, or sensitivity to components.

Who’s More Likely to Have Side Effects?

Risk isn’t random, and your care team tries to stack the deck in your favor. Factors that can increase the chance of complications include:

• History of frequent or severe infections
• Older age (in general) or significant medical comorbidities
• Use of additional immunosuppressants (like systemic steroids) at the same time
• Smoking (associated with worse Crohn’s outcomes overall)
• Uncontrolled diabetes or chronic lung disease
• Prior reactions to biologics or multiple prior biologic exposures

How Clinicians Reduce Risk (Before and During Treatment)

Biologics aren’t a “good luck!” situation. Most GI teams follow safety steps that look like this:

Before starting

• Screening: TB testing; hepatitis B (and sometimes other infection screening) depending on history and local protocols.
• Vaccines: updating recommended vaccines. Live vaccines are typically avoided during biologic therapy, so timing matters.
• Baseline labs: blood counts and liver enzymes, plus inflammation markers as appropriate.

During treatment

• Monitoring symptoms: fever, persistent cough, unusual fatigue, skin lesions, recurring infections.
• Periodic labs: especially if your specific biologic class is associated with lab changes.
• Skin awareness: because some immunosuppressing therapies can be associated with certain skin cancer risks, clinicians may recommend skin checks based on your overall risk profile.
• Adjustments when needed: changing dose schedule, switching drug class, addressing antibodies, or treating side effects promptly.

When to Contact Your Clinician Right Away

Call your clinician urgently (or seek emergency care) if you have symptoms like:

• High fever, severe chills, or signs of serious infection
• Shortness of breath, chest tightness, swelling of the face/throat, widespread hives
• Severe weakness, confusion, new neurologic symptoms (especially if on therapies associated with rare neurologic risks)
• Yellowing of the skin/eyes, dark urine, severe abdominal pain with abnormal labs

FAQs Patients Actually Ask (and Clinicians Actually Answer)

“Are biosimilars safer or riskier than brand-name biologics?”

Biosimilars are designed to be highly similar in safety and effectiveness to the reference biologic. In practice, the side-effect profiles are expected to be comparable, though your individual experience can still vary.

“Can I just stop if I feel weird?”

Don’t stop a biologic without guidance. Some side effects need urgent attention, but others are manageable with timing changes, supportive care, or switching strategies. Stopping abruptly can also risk a Crohn’s flare.

“Will I get sick all the time?”

Some people notice more frequent colds; others don’t. The goal is stable Crohn’s control with the lowest practical riskso if infections become frequent, your clinician may reassess dosing, class choice, and other contributing factors.

“Why do I need so many labs?”

Because the point is to catch issues earlywhen they’re easiest to fix. Monitoring is the boring superhero of biologic therapy.

Real-World Experiences (About ): What Living With Crohn’s Biologics Can Feel Like

Clinical trial charts are helpful, but they don’t capture the lived experience: the routines, the minor surprises, and the “is this normal?” moments that pop up between appointments. Here are common experiences patients often describe (shared here as illustrative patternsnot as personal medical advice).

The “First Dose Nerves” Are Real

Many people say the first infusion or first self-injection feels like a major eventeven if it goes smoothly. You might over-pack your bag for the infusion center (snacks, charger, hoodie, backup hoodie), or spend 20 minutes staring at the injection pen like it’s a tiny plastic judge. After a few doses, it often becomes routine: schedule it, do it, move on. The emotional load tends to shrink once the unknown becomes familiar.

Infusion Days Can Be… Surprisingly Normal

Patients often expect an infusion to knock them out for days. Some do feel tired afterward, but many report it’s more like “a slightly weird Tuesday.” People bring headphones, work, read, or nap. A common tip patients share is planning a lighter schedule after the first few infusionsjust in case fatigue shows upthen adjusting based on what their body actually does.

Injection-Site Reactions: The Most Annoying Tiny Problem

For self-injected biologics, the most commonly mentioned side effect is local irritation: redness, itching, a warm patch, or a bruise that looks dramatic but feels fine. Patients often report that rotating sites helps, as does being consistent with technique. Emotionally, it can be frustrating because it’s visiblelike your body leaving a sticky note that says, “Yes, I noticed the medicine.” The good news is many people say these reactions become milder over time.

The “Am I Getting Sick?” Mental Math

A frequent experience is second-guessing every sniffle. Is it a regular cold, or something bigger because you’re on a biologic? Patients often describe learning a new kind of body awareness: paying attention to fever, duration, severity, and how quickly symptoms escalate. Many find it reassuring to have a clear plan from their GI team about when to callso they’re not stuck in a loop of internet doom-scrolling at midnight.

Energy Improvements Can Feel Like Getting Your Life Back

When a biologic works well, patients often talk about benefits that go beyond fewer bathroom trips. They mention fewer “crash days,” more predictable energy, less anxiety about leaving the house, and the quiet joy of eating without immediate consequences. That contrastbetween uncontrolled inflammation and steadier controlis why many patients decide the risk/benefit tradeoff is worth it, even if they deal with occasional headaches or minor infections.

Insurance and Scheduling Can Be the Plot Twist

In the real world, side effects aren’t the only challenge. Prior authorizations, infusion center availability, and switching to biosimilars can add stress. Patients often say the most helpful approach is treating logistics like part of the care plan: keep a calendar, track doses, save documentation, and ask the clinic what support programs exist. It’s not glamorousbut it can prevent gaps in therapy, which can matter for Crohn’s control.

If you recognize yourself in any of these experiences, you’re not alone. Biologic therapy is as much a practical routine as it is a medical treatmentand building that routine (with good monitoring and clear communication) is often what turns “scary new drug” into “tool that helps me function.”